Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study
Hieken TJ et al. JAMA Surgery.
Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP)
Pazhava et al., Annals of Surgical Oncology
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). GalleryIdentification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral et al. 2022. European Journal of Cancer.
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis.
Thao et al. 2022. International Journal of Dermatology.
Using the Merlin Assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.
Hieken et al. 2022. International Journal of Dermatology.
- Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. Gallery
Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson et al. 2021. European Journal of Surgical Oncology.
Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study.
Yousaf & Tjien-Fooh et al., 2021. International Journal of Dermatology.
Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.
Arias-Mejias et al. 2020. International Journal of Dermatology.
Deselecting melanoma patients for sentinel lymph node biopsy during COVID-19: clinical utility of tumor molecular profiling.
Meves & Eggermont 2020. Mayo Clin Proc Inn Qual Out.